More than 600 neurological diseases – including Alzheimer, Parkinson, ALS, and Huntington – impact more than 50 million Americans. Yet these devastating diseases that cause the progressive loss of memory, mobility or both have no cure, and some are impossible to even predict.
At the HudsonAlpha Institute for Biotechnology, our researchers are investigating the genetic factors in neurological diseases. All neurological diseases are as interconnected as the nervous system itself. Finding answers to one disease may lead to answers about many. Our research has already led to the discovery of two new genes associated with ALS that suggest possible new directions for drug treatments.
In addition, HudsonAlpha researchers are searching for answers to psychiatric disorders such as major depression, bipolar and schizophrenia. We are using whole genome sequencing to identify genes and pathways that contribute to the risk for psychiatric disorders and identify targeted therapies and approaches for treatment.
The HudsonAlpha Foundation, a 501(c)(3) nonprofit organization, is the supporting entity for the HudsonAlpha Institute for Biotechnology. Tax-deductible contributions to the foundation are for the sole purpose of advancing the mission of the HudsonAlpha Institute for Biotechnology.
Tax identification #27-2320591